<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269605</url>
  </required_header>
  <id_info>
    <org_study_id>BRYOLAT</org_study_id>
    <nct_id>NCT02269605</nct_id>
  </id_info>
  <brief_title>Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment</brief_title>
  <acronym>BRYOLAT</acronym>
  <official_title>Bryostatin-1 Effect on HIV-1 Latency and Reservoir HIV-1 Infected Patients Receiving Antiretroviral Treatment: Pilot, Controlled, Double Blinded, Dose Searching Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, randomized, double blind, placebo-controlled, dose-finding trial. The trial´s goal
      is to evaluate two different doses of Bryostatin on HIV-1 latency and reservoir in HIV-1
      infected patients receiving antiretroviral treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracellular HIV-1 RNA (usRNA and msRNA) level before and after bryostatin-1 administration</measure>
    <time_frame>Baseline visit and days 2 and 3 after the day of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA level</measure>
    <time_frame>Baseline visit, day 0 (15, 30, 60 minutes after begining of drug administration and 1, 2, 4, 8, 12 hours after begining of drug administration) and days 1, 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ and CD8+ T (CD38+ and HLA DR+ positive) cell level</measure>
    <time_frame>Baseline visit, day 1 and day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episomal DNA with 2 LTRs level</measure>
    <time_frame>Baseline visit, day 1 and day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From baseline visit to day 28 after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving placebo (sodium chloride) at single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving Bryostatin 1 (10ug/m2) at single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving Bryostatin 1 (20ug/m2) at single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Group 1: Placebo (sodium chloride 0.8 %) at single dose</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bryostatin 1 (10ug/m2)</intervention_name>
    <description>Group 2: Bryostatin 1 (10ug/m2) at single dose</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bryostatin 1 (20ug/m2)</intervention_name>
    <description>Group 3: Bryostatin 1 (20ug/m2) at single dose</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients understanding the trial purpose

          -  Patients between 18 and 50 years of age

          -  Patients with chronic HIV-1 infection

          -  Patients receiving antiretroviral treatment with at least 3 active drugs for at least
             2 years

          -  Undetectable viral load measured by ultra sensitive methods

          -  CD4+ levels higher than 350 cells/mm3

          -  Patients committed to use contraceptive methods during the trial and up to 3 months
             after.

        Exclusion Criteria:

          -  Previous antiretroviral treatment failure, as any viral load outbreak after having had
             undetectable HIV-1 load. Low grade, transitory outbreaks (&lt;200 RNA copies/ml) resolved
             without treatment modifications are excluded

          -  Patients planned to interrupt antiretroviral treatment during the trial

          -  Patients receiving immunosuppressant or immunostimulant drugs, including valproic
             acid.

          -  Pregnant women

          -  Bryostatin-1 hypersensitivity

          -  Being enrolled in another clinical trial or having participated in another clinical
             trial in the previous 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Moreno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramón y Cajal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infectious Diseases Service</name>
      <address>
        <city>Madrid</city>
        <state>Non US/Canada</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Persaud D, Zhou Y, Siliciano JM, Siliciano RF. Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol. 2003 Feb;77(3):1659-65. Review.</citation>
    <PMID>12525599</PMID>
  </reference>
  <reference>
    <citation>Blankson JN, Gallant JE, Quinn TC, Bartlett JG, Siliciano RF. Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients. JAMA. 2002 Jul 10;288(2):162-4.</citation>
    <PMID>12095377</PMID>
  </reference>
  <reference>
    <citation>Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706. Review.</citation>
    <PMID>19265012</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV reservoir</keyword>
  <keyword>Bryostatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bryostatin 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

